The 3 analysts offering 12-month price forecasts for Outlook Therapeutics Inc have a median target of 7.00, with a high estimate of 8.00 and a low estimate of 6.00. The median estimate represents a +221.10% increase from the last price of 2.18.
The current consensus among 3 polled investment analysts is to Buy stock in Outlook Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.06
Reporting Date Dec 22
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.